PubRank

Joseph J Eron

Author PubWeight™ 298.91‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009 19.90
2 Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008 11.72
3 The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 2010 9.61
4 Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012 8.94
5 Brief but efficient: acute HIV infection and the sexual transmission of HIV. J Infect Dis 2004 8.30
6 Detection of acute infections during HIV testing in North Carolina. N Engl J Med 2005 7.60
7 Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003 5.79
8 The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 2009 5.72
9 Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis 2010 3.72
10 High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men. PLoS Pathog 2010 3.68
11 Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol 2007 3.46
12 Novel therapies based on mechanisms of HIV-1 cell entry. N Engl J Med 2003 3.32
13 The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med 2010 3.24
14 Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. JAMA 2002 2.96
15 Real-time, universal screening for acute HIV infection in a routine HIV counseling and testing population. JAMA 2002 2.94
16 Multiple V1/V2 env variants are frequently present during primary infection with human immunodeficiency virus type 1. J Virol 2004 2.91
17 The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res Hum Retroviruses 2002 2.89
18 Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. AIDS 2008 2.87
19 Invasive cervical cancer risk among HIV-infected women: a North American multicohort collaboration prospective study. J Acquir Immune Defic Syndr 2013 2.78
20 Frequent detection of acute primary HIV infection in men in Malawi. AIDS 2004 2.43
21 Acute HIV revisited: new opportunities for treatment and prevention. J Clin Invest 2004 2.30
22 Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection. Proc Natl Acad Sci U S A 2012 2.27
23 Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification. AIDS 2008 2.25
24 Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262). AIDS 2011 2.22
25 Late entry to HIV care among Latinos compared with non-Latinos in a southeastern US cohort. Clin Infect Dis 2011 2.20
26 Moving forward in HIV-associated cancer. J Clin Oncol 2014 2.14
27 Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis 2010 2.14
28 Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection. PLoS Med 2009 2.11
29 Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. Clin Infect Dis 2009 2.05
30 Psychiatric illness and virologic response in patients initiating highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2007 2.02
31 Prevalence of DSM-IV-defined mood, anxiety, and substance use disorders in an HIV clinic in the Southeastern United States. J Acquir Immune Defic Syndr 2006 2.01
32 A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS 2003 1.99
33 Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era. J Natl Cancer Inst 2013 1.96
34 Infrequent diagnosis of primary human immunodeficiency virus infection: missed opportunities in acute care settings. Arch Intern Med 2003 1.96
35 Viremia copy-years predicts mortality among treatment-naive HIV-infected patients initiating antiretroviral therapy. Clin Infect Dis 2011 1.91
36 Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr 2005 1.87
37 Factors associated with fewer visits for HIV primary care at a tertiary care center in the Southeastern U.S. AIDS Care 2006 1.76
38 Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. Ann Intern Med 2014 1.75
39 Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study. AIDS 2004 1.74
40 Splines for trend analysis and continuous confounder control. Epidemiology 2011 1.69
41 Pre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost? Clin Infect Dis 2011 1.68
42 Copy-years viremia as a measure of cumulative human immunodeficiency virus viral burden. Am J Epidemiol 2009 1.63
43 Gender difference in HIV RNA levels: a meta-analysis of published studies. J Acquir Immune Defic Syndr 2002 1.59
44 Enrollment, retention, and visit attendance in the University of North Carolina Center for AIDS Research HIV clinical cohort, 2001-2007. AIDS Res Hum Retroviruses 2010 1.58
45 Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections. PLoS Pathog 2011 1.57
46 CD4+CD8+ T cells represent a significant portion of the anti-HIV T cell response to acute HIV infection. J Immunol 2012 1.57
47 Emergence of HIV drug resistance during first- and second-line antiretroviral therapy in resource-limited settings. J Infect Dis 2013 1.55
48 Modeling long-term HIV dynamics and antiretroviral response: effects of drug potency, pharmacokinetics, adherence, and drug resistance. J Acquir Immune Defic Syndr 2005 1.52
49 A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease. J Infect Dis 2003 1.51
50 Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. J Acquir Immune Defic Syndr 2005 1.50
51 Comparison of two indinavir/ritonavir regimens in the treatment of HIV-infected individuals. J Acquir Immune Defic Syndr 2004 1.48
52 HIV Salvage Therapy Does Not Require Nucleoside Reverse Transcriptase Inhibitors: A Randomized, Controlled Trial. Ann Intern Med 2015 1.47
53 No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy. J Infect Dis 2010 1.45
54 Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy. J Infect Dis 2011 1.45
55 Frequent detection of acute HIV infection in pregnant women. AIDS 2007 1.43
56 Incidence and etiology of acute renal failure among ambulatory HIV-infected patients. Kidney Int 2005 1.40
57 Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr 2006 1.40
58 No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy. J Acquir Immune Defic Syndr 2012 1.39
59 Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care. AIDS 2012 1.38
60 Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068. J Infect Dis 2006 1.37
61 Pharmacokinetics and pharmacodynamics of once-daily versus twice-daily raltegravir in treatment-naive HIV-infected patients. Antimicrob Agents Chemother 2012 1.36
62 Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients. AIDS 2007 1.33
63 Cross-sectional detection of acute HIV infection: timing of transmission, inflammation and antiretroviral therapy. PLoS One 2011 1.32
64 Incidence and timing of cancer in HIV-infected individuals following initiation of combination antiretroviral therapy. Clin Infect Dis 2013 1.31
65 Advanced immunosuppression at entry to HIV care in the southeastern United States and associated risk factors. AIDS 2006 1.30
66 Joint effects of alcohol consumption and high-risk sexual behavior on HIV seroconversion among men who have sex with men. AIDS 2013 1.27
67 HIV-1 drug resistance evolution among patients on potent combination antiretroviral therapy with detectable viremia. J Acquir Immune Defic Syndr 2005 1.23
68 High levels of antiretroviral use and viral suppression among persons in HIV care in the United States, 2010. J Acquir Immune Defic Syndr 2013 1.23
69 Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009-2012. Clin Infect Dis 2013 1.23
70 Expression of p16(INK4a) as a biomarker of T-cell aging in HIV-infected patients prior to and during antiretroviral therapy. Aging Cell 2012 1.21
71 Perceived oral health status, unmet needs, and barriers to dental care among HIV/AIDS patients in a North Carolina cohort: impacts of race. J Public Health Dent 2003 1.20
72 Prevalence and comorbidity of psychiatric diagnoses based on reference standard in an HIV+ patient population. Psychosom Med 2008 1.19
73 Phylogenetic insights into regional HIV transmission. AIDS 2012 1.18
74 Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II study. J Acquir Immune Defic Syndr 2010 1.17
75 Addition of 7 days of zidovudine plus lamivudine to peripartum single-dose nevirapine effectively reduces nevirapine resistance postpartum in HIV-infected mothers in Malawi. J Acquir Immune Defic Syndr 2010 1.15
76 Incidence and clinical features of cerebrovascular disease among HIV-infected adults in the Southeastern United States. AIDS Res Hum Retroviruses 2013 1.15
77 Acute HIV-1 infection in the Southeastern United States: a cohort study. AIDS Res Hum Retroviruses 2012 1.14
78 Investigating a sexual network of black men who have sex with men: implications for transmission and prevention of HIV infection in the United States. J Acquir Immune Defic Syndr 2012 1.14
79 CD4 count at presentation for HIV care in the United States and Canada: are those over 50 years more likely to have a delayed presentation? AIDS Res Ther 2010 1.13
80 Immunosuppression, hepatitis C infection, and acute renal failure in HIV-infected patients. J Acquir Immune Defic Syndr 2006 1.12
81 Risk factors for tuberculosis after highly active antiretroviral therapy initiation in the United States and Canada: implications for tuberculosis screening. J Infect Dis 2011 1.11
82 Prevalence of transmitted antiretroviral drug resistance differs between acutely and chronically HIV-infected patients. J Acquir Immune Defic Syndr 2012 1.11
83 Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction. J Acquir Immune Defic Syndr 2004 1.10
84 Validation of a brief screening instrument for substance abuse and mental illness in HIV-positive patients. J Acquir Immune Defic Syndr 2005 1.09
85 Neurocognitive functioning and HAART in HIV and hepatitis C virus co-infection. AIDS 2006 1.08
86 Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. J Infect Dis 2002 1.07
87 Pharmacokinetic and pharmacodynamic investigation of efavirenz in the semen and blood of human immunodeficiency virus type 1-infected men. J Infect Dis 2002 1.07
88 Substance abuse and symptoms of mental illness among HIV-positive persons in the Southeast. South Med J 2005 1.06
89 Envelope diversity, coreceptor usage and syncytium-inducing phenotype of HIV-1 variants in saliva and blood during primary infection. AIDS 2003 1.05
90 Barriers and facilitators to HIV testing and linkage to primary care: narratives of people with advanced HIV in the Southeast. AIDS Care 2009 1.05
91 Pharmacodynamics of antiretroviral agents in HIV-1 infected patients: using viral dynamic models that incorporate drug susceptibility and adherence. J Pharmacokinet Pharmacodyn 2006 1.05
92 Macrophages sustain HIV replication in vivo independently of T cells. J Clin Invest 2016 1.04
93 Selection Bias Due to Loss to Follow Up in Cohort Studies. Epidemiology 2016 1.04
94 Systemically circulating viral and tumor-derived microRNAs in KSHV-associated malignancies. PLoS Pathog 2013 1.04
95 Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine. AIDS 2003 1.02
96 The pharmacokinetics of amprenavir, zidovudine, and lamivudine in the genital tracts of men infected with human immunodeficiency virus type 1 (AIDS clinical trials group study 850). J Infect Dis 2002 1.01
97 HIV viremia and incidence of non-Hodgkin lymphoma in patients successfully treated with antiretroviral therapy. Clin Infect Dis 2014 1.00
98 Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection. AIDS 2011 0.99
99 The detection and management of early HIV infection: a clinical and public health emergency. J Acquir Immune Defic Syndr 2013 0.98
100 Safety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients: 48-week results from the REALMRK Study. AIDS Res Hum Retroviruses 2013 0.97
101 HIV-1 protease inhibitors and clinical malaria: a secondary analysis of the AIDS Clinical Trials Group A5208 study. Antimicrob Agents Chemother 2011 0.96
102 Estimation of the standardized risk difference and ratio in a competing risks framework: application to injection drug use and progression to AIDS after initiation of antiretroviral therapy. Am J Epidemiol 2014 0.96
103 HIV risk behaviors and sociodemographic features of HIV-infected Latinos residing in a new Latino settlement area in the Southeastern United States. AIDS Care 2013 0.95
104 Antiretroviral therapy initiated during acute HIV infection fails to prevent persistent T-cell activation. J Acquir Immune Defic Syndr 2013 0.95
105 The frequency of malaria is similar among women receiving either lopinavir/ritonavir or nevirapine-based antiretroviral treatment. PLoS One 2012 0.95
106 Meta-analysis of randomized trials on the association of prophylactic acyclovir and HIV-1 viral load in individuals coinfected with herpes simplex virus-2. AIDS 2011 0.93
107 Self-report of current and prior antiretroviral drug use in comparison to the medical record among HIV-infected patients receiving primary HIV care. Pharmacoepidemiol Drug Saf 2011 0.93
108 The effect of tuberculosis treatment on virologic and CD4+ cell count response to combination antiretroviral therapy: a systematic review. AIDS 2014 0.93
109 Association of early HIV viremia with mortality after HIV-associated lymphoma. AIDS 2013 0.92
110 Sexually transmitted infections among patients with acute HIV in North Carolina. Sex Transm Dis 2009 0.92
111 Social network-based recruitment successfully reveals HIV-1 transmission networks among high-risk individuals in El Salvador. J Acquir Immune Defic Syndr 2013 0.92
112 Intracellular nucleoside triphosphate concentrations in HIV-infected patients on dual nucleoside reverse transcriptase inhibitor therapy. Antivir Ther 2007 0.91
113 Effect of hepatitis C coinfection on discontinuation and modification of initial HAART in primary HIV care. AIDS 2006 0.91
114 TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals. AIDS Patient Care STDS 2007 0.90
115 Predictors of residual viraemia in patients on long-term suppressive antiretroviral therapy. Antivir Ther 2012 0.90
116 Performance characteristics of the Cavidi ExaVir viral load assay and the ultra-sensitive P24 assay relative to the Roche Monitor HIV-1 RNA assay. J Clin Virol 2010 0.90
117 A randomized trial of nelfinavir and abacavir in combination with efavirenz and adefovir dipivoxil in HIV-1-infected persons with virological failure receiving indinavir. Antivir Ther 2003 0.90
118 A brief mental health and substance abuse screener for persons with HIV. AIDS Patient Care STDS 2005 0.89
119 The pharmacokinetics, safety, and initial virologic response of a triple-protease inhibitor salvage regimen containing amprenavir, saquinavir, and ritonavir. J Acquir Immune Defic Syndr 2004 0.89
120 Decreasing excess mortality of HIV-infected patients initiating antiretroviral therapy: comparison with mortality in general population in China, 2003-2009. J Acquir Immune Defic Syndr 2013 0.89
121 Regimen selection in the OPTIONS trial of HIV salvage therapy: drug resistance, prior therapy, and race-ethnicity determine the degree of regimen complexity. HIV Clin Trials 2015 0.89
122 Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naïve HIV-1-infected patients. HIV Clin Trials 2008 0.88
123 Associations of T cell activation and inflammatory biomarkers with virological response to darunavir/ritonavir plus raltegravir therapy. J Antimicrob Chemother 2013 0.88
124 Activity, safety, and immunological effects of hydroxyurea added to didanosine in antiretroviral-naive and experienced HIV type 1-infected subjects: a randomized, placebo-controlled trial, ACTG 307. AIDS Res Hum Retroviruses 2004 0.88
125 Social support and delays seeking care after HIV diagnosis, North Carolina, 2000-2006. AIDS Care 2009 0.87
126 Analysis of virological efficacy in trials of antiretroviral regimens: drawbacks of not including viral load measurements after premature discontinuation of therapy. Antivir Ther 2002 0.87
127 Age at antiretroviral therapy initiation predicts immune recovery, death, and loss to follow-up among HIV-infected adults in urban Zambia. AIDS Res Hum Retroviruses 2014 0.87
128 Major coexisting human immunodeficiency virus type 1 env gene subpopulations in the peripheral blood are produced by cells with similar turnover rates and show little evidence of genetic compartmentalization. J Virol 2009 0.87
129 Raltegravir pharmacokinetics in treatment-naive patients is not influenced by race: results from the raltegravir early therapy in African-Americans living with HIV (REAL) study. Antimicrob Agents Chemother 2012 0.87
130 Simplifying antiretroviral therapy. AIDS Read 2004 0.86
131 Short-term safety and pharmacodynamics of amdoxovir in HIV-infected patients. AIDS 2005 0.86
132 Recent cancer incidence trends in an observational clinical cohort of HIV-infected patients in the US, 2000 to 2011. Infect Agent Cancer 2013 0.86
133 Variability of the date of HIV diagnosis: a comparison of self-report, medical record, and HIV/AIDS surveillance data. Ann Epidemiol 2010 0.85
134 The Impact of Implementation Fidelity on Mortality Under a CD4-Stratified Timing Strategy for Antiretroviral Therapy in Patients With Tuberculosis. Am J Epidemiol 2015 0.85
135 The design of single-arm clinical trials of combination antiretroviral regimens for treatment-naive HIV-infected patients. AIDS Res Hum Retroviruses 2013 0.85
136 High-dose lopinavir/ritonavir in highly treatment-experienced HIV-1 patients: efficacy, safety, and predictors of response. HIV Clin Trials 2007 0.85
137 HIV-1 viral load and phenotypic antiretroviral drug resistance assays based on reverse transcriptase activity in comparison to amplification based HIV-1 RNA and genotypic assays. J Clin Virol 2009 0.85
138 African American race and HIV virological suppression: beyond disparities in clinic attendance. Am J Epidemiol 2014 0.85
139 Poorly Controlled HIV Infection: An Independent Risk Factor for Liver Fibrosis. J Acquir Immune Defic Syndr 2016 0.84
140 Clinical presentation, treatment, and outcomes among 65 patients with HIV-associated lymphoma treated at the University of North Carolina, 2000-2010. AIDS Res Hum Retroviruses 2011 0.84
141 Evaluating the Effect of Early Versus Late ARV Regimen Change if Failure on an Initial Regimen: Results From the AIDS Clinical Trials Group Study A5095. J Am Stat Assoc 2012 0.84
142 Naïve T cells are maintained in the periphery during the first 3 months of acute HIV-1 infection: implications for analysis of thymus function. J Clin Immunol 2005 0.84
143 Outcomes of second combination antiretroviral therapy regimens among HIV-infected persons in clinical care: a multicenter cohort study. AIDS Res Hum Retroviruses 2012 0.84
144 Residual plasma viraemia and infectious HIV-1 recovery from resting memory CD4 cells in patients on antiretroviral therapy: results from ACTG A5173. Antivir Ther 2013 0.83
145 Emotional distress in African American women with HIV. J Prev Interv Community 2007 0.83
146 Effects of formulation and dosing strategy on amprenavir concentrations in the seminal plasma of human immunodeficiency virus type 1-infected men. Clin Infect Dis 2002 0.83
147 Treatment responses in antiretroviral treatment-naive premenopausal and postmenopausal HIV-1-infected women: an analysis from AIDS Clinical Trials Group Studies. Clin Infect Dis 2009 0.82
148 Hepatic safety and tolerability of raltegravir among HIV patients coinfected with hepatitis B and/or C. Antivir Ther 2014 0.82
149 Viral suppression in HIV studies: combining times to suppression and rebound. Biometrics 2014 0.82
150 Does HAART efficacy translate to effectiveness? Evidence for a trial effect. PLoS One 2011 0.82
151 Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study. J Acquir Immune Defic Syndr 2013 0.82
152 Factors associated with delayed hepatitis B viral suppression on tenofovir among patients coinfected with HBV-HIV in the CNICS cohort. J Acquir Immune Defic Syndr 2014 0.82
153 Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience. HIV Clin Trials 2008 0.81
154 Relationship of immunologic response to antiretroviral therapy with non-AIDS defining cancer incidence. AIDS 2014 0.81
155 Effect of hydroxyurea and dideoxyinosine on intracellular 3'-deoxyadenosine-5'-triphosphate concentrations in HIV-infected patients. AIDS Res Hum Retroviruses 2007 0.81
156 The role of at-risk alcohol/drug use and treatment in appointment attendance and virologic suppression among HIV(+) African Americans. AIDS Res Hum Retroviruses 2014 0.81
157 Validation of Medicaid Claims-based Diagnosis of Myocardial Infarction Using an HIV Clinical Cohort. Med Care 2015 0.81
158 Effects of combination antiretroviral therapies on the risk of myocardial infarction among HIV patients. Epidemiology 2014 0.81
159 Chagasic encephalitis as the initial manifestation of AIDS. Ann Intern Med 2006 0.81
160 Aciclovir treatment for human immunodeficiency virus-1: is the “juice worth the squeeze?”. Sex Transm Dis 2011 0.80
161 The effect of lamivudine therapy and M184V on the antiretroviral activity of didanosine. J Acquir Immune Defic Syndr 2007 0.80
162 Comparative effectiveness of fish oil versus fenofibrate, gemfibrozil, and atorvastatin on lowering triglyceride levels among HIV-infected patients in routine clinical care. J Acquir Immune Defic Syndr 2013 0.79
163 Ten Years of Screening and Testing for Acute HIV Infection in North Carolina. J Acquir Immune Defic Syndr 2016 0.79
164 Brief Report: HIV Drug Resistance in Adults Failing Early Antiretroviral Treatment: Results From the HIV Prevention Trials Network 052 Trial. J Acquir Immune Defic Syndr 2016 0.79
165 Severe postvaccinia encephalitis with acute disseminated encephalomyelitis: recovery with early intravenous immunoglobulin, high-dose steroids, and vaccinia immunoglobulin. Clin Infect Dis 2009 0.79
166 Incident sexually transmitted infection as a biomarker for high-risk sexual behavior after diagnosis of acute HIV. Sex Transm Dis 2014 0.78
167 Opportunities for sexual transmission of antiretroviral drug resistance among HIV-infected patients in care. AIDS 2013 0.78
168 Hematologic, hepatic, renal, and lipid laboratory monitoring after initiation of combination antiretroviral therapy in the United States, 2000-2010. J Acquir Immune Defic Syndr 2013 0.78
169 Large scale screening of human sera for HCV RNA and GBV-C RNA. J Med Virol 2013 0.78
170 Phylogenetic evidence of HIV-1 sequence evolution in subjects with persistent low-level viraemia. Antivir Ther 2014 0.78
171 Dose separation does not overcome the pharmacokinetic interaction between fosamprenavir and lopinavir/ritonavir. Antimicrob Agents Chemother 2006 0.78
172 When to Monitor CD4 Cell Count and HIV RNA to Reduce Mortality and AIDS-Defining Illness in Virologically Suppressed HIV-Positive Persons on Antiretroviral Therapy in High-Income Countries: A Prospective Observational Study. J Acquir Immune Defic Syndr 2016 0.78
173 Fixed-dose combination emtricitabine/tenofovir/efavirenz initiated during acute HIV infection; 96-week efficacy and durability. AIDS 2016 0.78
174 Evidence for risk stratification when monitoring for toxicities following initiation of combination antiretroviral therapy. AIDS 2013 0.77
175 Short communication: lack of occult HIV infection among non-AIDS-defining cancer patients in three academic oncology clinics in the United States. AIDS Res Hum Retroviruses 2013 0.77
176 Modeling clinical endpoints as a function of time of switch to second-line ART with incomplete data on switching times. Biometrics 2013 0.77
177 Low prevalence of antiretroviral resistance among HIV type 1-positive prisoners in the Southeast United States. AIDS Res Hum Retroviruses 2012 0.77
178 Increased Risk of Myocardial Infarction in HIV-Infected Individuals in North America Compared to the General Population. J Acquir Immune Defic Syndr 2017 0.76
179 Multiple Imputation to Account for Measurement Error in Marginal Structural Models. Epidemiology 2015 0.76
180 Determination of amprenavir, a HIV-1 protease inhibitor, in human seminal plasma using high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2002 0.76
181 Smoking and predictors of pneumonia among HIV-infected patients receiving care in the HAART era. Open Respir Med J 2008 0.76
182 Massive CD8 T cell response to primary HIV infection in the setting of severe clinical presentation. AIDS Res Hum Retroviruses 2012 0.76
183 Reply to P. De Paoli et al. J Clin Oncol 2014 0.75
184 Neurocognition with maraviroc compared with tenofovir in HIV. AIDS 2016 0.75
185 Impact of Health Insurance, ADAP, and Income on HIV Viral Suppression Among US Women in the Women's Interagency HIV Study, 2006-2009. J Acquir Immune Defic Syndr 2016 0.75
186 Evaluating the incident user design in the HIV population: incident use versus naive? Pharmacoepidemiol Drug Saf 2014 0.75
187 Antiretroviral activity and safety of once-daily etravirine in treatment-naive HIV-infected adults: 48-week results. Antivir Ther 2015 0.75
188 Differential CD4+ cell count increase and CD4+ :  CD8+ ratio normalization with maraviroc compared with tenofovir. AIDS 2016 0.75
189 Brief Report: Longitudinal Opioid Use Among HIV-Infected Patients, 2000 to 2014. J Acquir Immune Defic Syndr 2017 0.75
190 Increased Persistence of Initial Treatment for HIV Infection with Modern Antiretroviral Therapy. J Acquir Immune Defic Syndr 2017 0.75
191 Incomplete viral suppression and mortality in HIV patients after antiretroviral therapy initiation. AIDS 2017 0.75
192 Risk factors for atrial fibrillation in a multi-center US clinical cohort of people with HIV infection. AIDS 2022 0.75
193 The relationship between efavirenz as initial antiretroviral therapy and suicidal thoughts among HIV-infected adults in routine care. J Acquir Immune Defic Syndr 2017 0.75
194 Expert offers help for PI-related heart disease. AIDS Alert 2002 0.75
195 Unexpected finding of delayed-onset seizures in HIV-positive, treatment-experienced subjects in the Phase IIb evaluation of fosdevirine (GSK2248761). Antivir Ther 2013 0.75
196 HIV Care Initiation Delay among Rural Residents in the Southeastern United States, 1996 to 2012. J Acquir Immune Defic Syndr 2017 0.75
197 Pretreatment integrase strand transfer inhibitor resistance in North Carolina from 2010-2016. AIDS 2017 0.75
198 Pre-treatment integrase strand transfer inhibitor resistance in north carolina from 2010-2016. AIDS 2017 0.75
199 Evaluating the Population Impact of Intervening on Specific Targets to Reduce HIV Racial/Ethnic Disparities in Adulthood: a Conceptual and Methodological Framework. Am J Epidemiol 2017 0.75
200 14th annual retrovirus conference (CROI). One-on-one with Joseph J. Eron, MD. Interview by Jeff Berry. Posit Aware 2007 0.75